Clinical trial
Lovastatin in Treating Patients At High Risk of Melanoma
NCT00462280 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00462280 |
|---|---|
| Title | Lovastatin in Treating Patients At High Risk of Melanoma |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Precancerous Condition, Stage 0 Melanoma, Stage I Melanoma, Stage II Melanoma |
| Intervention type | Drug, Other, Procedure |
| Interventions | lovastatin, placebo, biopsy, laboratory biomarker analysis |
| Enrollment | 80 |
| Start date | May 1, 2007 |
| Primary completion | Apr 1, 2011 |
| Completion | Feb 1, 2012 |
| First posted | Apr 19, 2007 |
| Last update posted | Oct 31, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: